Pressure on pharmaceutical companies to lower the price of expensive cancer drugs was ramped up on Thursday after NICE, the UK's National Institute for Clinical Excellence, rejected four drugs that treat advanced kidney cancer. In an appraisal consultation document, NICE recommended against making Pfizer's Sutent, Roche's Avastin, Bayer's and Onyx's Nexavar and Wyeth's Torisel available on the NHS to treat patients with advanced or metastatic renal cell carcinoma.
In draft guidance – which is subject to consultation and then to appeal if the decision stands – NICE accepted that the treatments were clinically effective.
“Regrettably, however, the cost to the NHS is such that they are not a cost-effective use of NHS resources,” Prof Peter Littlejohns, NICE’s clinical director, concluded.
More at the FT
In draft guidance – which is subject to consultation and then to appeal if the decision stands – NICE accepted that the treatments were clinically effective.
“Regrettably, however, the cost to the NHS is such that they are not a cost-effective use of NHS resources,” Prof Peter Littlejohns, NICE’s clinical director, concluded.
More at the FT
BUT
This post ( excellent job Matt) helps to explain the whole thing.
No comments:
Post a Comment